In vivo effects in mice produced by a 3'-branched homologue of alpha-2'-deoxythioguanosine

• Published in: Cancer chemotherapy and pharmacology 1980, Vol.5 (2), p.127
• Main Authors: LePage, G A, Banks, P A, Noujaim, M J, Buzzell, G R
• Format: Article
• Language: English
• Subjects: Animals; Bone Marrow - drug effects; Deoxyguanosine - analogs & derivatives; Deoxyguanosine - metabolism; Deoxyguanosine - pharmacology; Deoxyguanosine - toxicity; Dideoxynucleosides; DNA - metabolism; DNA, Neoplasm - metabolism; Female; Lymphoma, Non-Hodgkin - drug therapy; Mice; Neoplasms, Experimental - drug therapy; Thionucleosides - metabolism; Thionucleosides - pharmacology; Thionucleosides - toxicity
• ISSN: 0344-5704
• DOI: 10.1007/BF00435416

Studies with a 3'-branched chain homolog (alpha-3'-BCTGdR) of 2'-deoxythioguanosine (alpha-TGdR) showed that it did not prolong the survival of mice bearing the Mecca lymphosarcoma. Host toxicity was quite profound and resembled that seen with 6-thioguanine (6-TG). Evidence was obtained that this nucleoside derivative was not appreciably converted to 6-TG in the mouse. Mice treated with toxic doses of 6-TG or alpha-3'-BCTGdR were found to have very similar pathological changes. The granulocytes were eliminated from the peripheral blood, bone marrow was acellular, and some more limited damage was seen in the intestinal crypts. Experiments with radiosulfur-labeled drugs demonstrated that alpha-3'-BCTGdR was incorporated into the DNA of mouse bone marrow, predominantly in the chain-terminating position, with the result that shorter chains of DNA accumulated. The new homolog, unlike alpha-TGdR, was phosphorylated in bone marrow as well as in tumor, and incorporated well into the DNA both of bone marrow and of the neoplastic cells. In devising other homologs attention must be given to the specificity of the kinases, i.e., to whether phosphorylation is superior in tumor cells or in the growing normal cells.